Researchers found that Aardvark Therapeutics’ new drug ARD-101, designed to help manage insatiable hunger in people with Prader-Willi Syndrome (PWS), is currently on hold by the U.S. Food and Drug Administration (FDA). This pause affects all ongoing studies related to the drug, including a key Phase 3 trial. Aardvark is actively working with the FDA to resolve the hold and ensure patient safety while they analyze the data collected so far.

This development is significant for individuals with PWS, a rare genetic disorder that leads to extreme hunger and can result in obesity and other health issues. If successful, ARD-101 could potentially help these individuals manage their hunger better, improving their quality of life and reducing associated health risks. So far, 68 patients have participated in the main trial, which aims to evaluate the drug’s effectiveness and safety.

Currently, the research is in the early stages, with the FDA’s clinical hold creating uncertainty about the drug’s future. While Aardvark is committed to advancing the therapy, the hold means that the drug is not yet available for public use. The company plans to review the data from its trials to determine the best next steps, but until the hold is lifted, the timeline for ARD-101’s potential approval remains unclear.

For those interested in the treatment landscape for PWS, staying informed about Aardvark’s progress and the FDA’s decisions will be crucial. Engaging with advocacy groups and medical professionals can also provide support and updates on emerging therapies for this condition.

Source: globenewswire.com